Stock Split Watch: Is Eli Lilly Next?
Eli Lilly (NYSE: LLY) may not immediately come to mind when you think of growth stocks. Instead, you might think of technology or even consumer-oriented players. But Lilly actually has shown itself to be a top growth player in recent quarters, and this is thanks to its strength in one particular market: the obesity drug market.
Lilly has slipped ahead of rival Novo Nordisk to control the GLP-1 drug market in the U.S., now holding about 60% share. This is a big deal considering the high demand for these weight loss drugs, which has translated into blockbuster revenue.
Investors, recognizing this, have piled into Lilly stock -- over the past three years, the shares have advanced more than 160%. Lilly, along with other growth stocks, struggled in the first months of this year, but over the past month, the stock has rocketed higher, surpassing $1,000.
Source Fool.com
